Protocolo de Actuación en Mieloma múltiple - Sociedad Asturiana ...

BIBLIOGRAFIA
1. Alegre A, Oriol A, Duncan C et al. Efficacy, safety and quality of life of lenalidomide plus
dexametasone for the treatment of relapsed or refractory multiple myeloma: the Spanish
experience. Leukemia and Lymphoma 2012 (accepted for publication)
2. Avet-Loiseau et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients
with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus
dexametasone. Leukemia 2010; 24: 623-28
3. Barlogie et la. EDAP in refractory multiple myeloma. J Clin Oncol 1989; 7: 1514-7
4. Barlogie et al. Incorporating Bortezomib into upfront treatment for multiple myeloma: early
results of total therapy 3. Br J Haematol 2007; 138; 176-185
5. Bird J, Owen R, D´Sa et al. (BCSH and UK Myeloma Forum) Guidelines for the diagnosed
and management of multiple myeloma 2011. Br J Haematol 2011: 154: 32-75
6. Blade J, Rosiñol L, Cibeira T et al. Hematopoietic stem cell transplantation for multiple
myeloma beyond 2010. Blood 2010; 115:3655-3663
7. Chaldon et al. Second autologous stem cell transplantation is effective salvage therapy for
relapsed or refractory multiple myeloma.Blood 2009; 114: abst. 1229
8. Davies et al. The combination of cyclophosphamide, vecade and dexamethasone induces high
response rates with comparable toxicity to Velcade alone and Velcade and dexamethasone.
Haematologica 2007;92: 1149-50
9. Dimopoulos MA, Spencer A, Attal M et al. Multiple Myeloma (010) Study Investigators.
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J
Med. 2007; 357:2123-32
10. Dimopoulus MA, Palumbo A, Attal M et al. Optimizing the use of lenalidomide in relapsed or
refractory multiple myeloma: consensus statement. Leukemia 2011; 25: 749-760
11. Fenk et al. Reapplication of high doses chemotherapy and autologous blood stem cell
transplantation as salvage treatment for patients with relapsed multiple myeloma. Blood 2009;
114: abst. 3418
12. Harousseau J, Dimopoulus MA, Stadtmauer E et al. Better quality of response to lenalidomide
plus dexametasone is associated with improved clinical outcomes in patients with relapsed or
refractory multiple myeloma. Haematologica 2010; 95: 1738-44
13. Hrusovsky I and Heidtmann H. Combination Therapy of Bortezomib with Bendamustine in
Elderly Patients with Advanced Multiple Myeloma. Clinical Observation.. Blood 2007; 110:
abst. 4851.
14. Knop S, Gerecke C, Liebischh P et al. Lenalidomide, adriamycin and dexametasone (RAD) in
patients with relapsed and refractory multiple myeloma: a report fron the German Myeloma
Study DSMM. Blood 2009; 113: 4137-43
15. Kropft M, Bisping G, Chuck E et al. Bortezomib in combination with intermediate-dose
dexamthasone and continuos low dose oral cyclophsphamide for relapsed multiple myeloma.
Br J Haematol 2007; 138: 330-2
Grupo Asturiano de Linfoma y Mieloma
69